Q4 2024 Earnings Call Transcript February 4, 2025 Dassault Systèmes SE beats earnings expectations. Reported EPS is $0.43, ...

Before we begin, I want to thank the 40,000-plus global Cencora team members ... I think you guys are the largest distributor for Regeneron on Eylea, and Amgen just launched--I think they ...

Thus, I will be providing you with my view on EDIT and NTLA ... among others. In 2022, the global HAE market size was estimated at $3.3 billion, and it is expected to grow at 7.4% CAGR until ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported fourth-quarter earnings of $917.7 million. On a per-share basis, the Tarrytown ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

Regeneron (NASDAQ:REGN ... These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds. This article was generated ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... patient’s tumor in view. Statistics from Grand View Research show that the global precision oncology market ...

Regeneron stock rose early Tuesday on a strong fourth-quarter report that included in-line sales of eye drug Eylea.

We note that Sanofi records global net product sales of Dupixent and Kevzara, while Regeneron records its share of profits/losses in connection with the global sales of both drugs. Dupixent’s ...